Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Phase 3 Terminated
55 enrolled
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Phase 1/2 Terminated
10 enrolled 15 charts
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Terminated
94 enrolled 28 charts
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Phase 3 Terminated
96 enrolled 16 charts
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
70 enrolled 24 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Phase 2 Terminated
7 enrolled 10 charts
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Phase 2 Terminated
148 enrolled 9 charts
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Phase 2 Terminated
7 enrolled 8 charts
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Phase 1 Terminated
34 enrolled
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)
Phase 2/3 Terminated
27 enrolled
GELATO
Phase 2 Terminated
23 enrolled
DETECT
Phase 2 Terminated
12 enrolled
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Terminated
102 enrolled 51 charts
PREDIXIIHER2
Phase 2 Terminated
6 enrolled
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Phase 2 Terminated
6 enrolled
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
Phase 2 Terminated
30 enrolled 6 charts
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
107 enrolled
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 2 Terminated
5 enrolled
Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD
Phase 2/3 Terminated
12 enrolled
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Phase 1/2 Terminated
31 enrolled
BETH
Phase 3 Terminated
3,509 enrolled
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Phase 1/2 Terminated
12 enrolled
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
Phase 1 Terminated
15 enrolled 8 charts
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
Phase 2 Terminated
10 enrolled 8 charts
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
Phase 2 Terminated
7 enrolled 3 charts
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Phase 1 Terminated
14 enrolled
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase 1/2 Terminated
12 enrolled 12 charts
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Phase 2 Terminated
10 enrolled 8 charts
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Phase 1 Terminated
11 enrolled
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
Phase 2 Terminated
11 enrolled 5 charts
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
Phase 2 Terminated
5 enrolled 6 charts
Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery
Phase 2 Terminated
16 enrolled
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
Phase 3 Terminated
602 enrolled
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Phase 2 Terminated
88 enrolled